BioScrip, Inc. (NASDAQ:BIOS) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 18,783,163 shares, a decline of 11.6% from the August 15th total of 21,241,640 shares. Currently, 14.8% of the shares of the stock are sold short. Based on an average daily volume of 2,028,727 shares, the days-to-cover ratio is currently 9.3 days.

In other BioScrip news, Director Coliseum Capital Management, L sold 2,846,941 shares of BioScrip stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total transaction of $8,341,537.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its stake in BioScrip by 1.0% in the second quarter. Wells Fargo & Company MN now owns 114,810 shares of the company’s stock valued at $312,000 after acquiring an additional 1,100 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in BioScrip by 0.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 490,698 shares of the company’s stock valued at $1,333,000 after buying an additional 2,622 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in BioScrip by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 99,569 shares of the company’s stock valued at $271,000 after buying an additional 8,914 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of BioScrip by 9.2% during the 2nd quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock valued at $353,000 after buying an additional 10,985 shares in the last quarter. Finally, Sheets Smith Wealth Management lifted its stake in shares of BioScrip by 13.4% during the 2nd quarter. Sheets Smith Wealth Management now owns 125,328 shares of the company’s stock valued at $340,000 after buying an additional 14,820 shares in the last quarter. 84.05% of the stock is currently owned by institutional investors and hedge funds.

BioScrip (BIOS) opened at 2.67 on Monday. The firm’s market capitalization is $340.36 million. The stock has a 50 day moving average price of $2.87 and a 200 day moving average price of $2.26. BioScrip has a one year low of $0.98 and a one year high of $3.43.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The company had revenue of $218.11 million for the quarter, compared to analyst estimates of $220.05 million. BioScrip’s revenue was down 6.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.14) earnings per share. On average, equities analysts predict that BioScrip will post ($0.55) EPS for the current fiscal year.

Several research analysts have recently commented on BIOS shares. Barrington Research boosted their target price on BioScrip to $3.50 and gave the stock an “outperform” rating in a report on Monday, June 26th. Zacks Investment Research raised BioScrip from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Wednesday, July 5th. ValuEngine downgraded BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $4.00 target price (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. Finally, BidaskClub downgraded BioScrip from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $3.75.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/18/bioscrip-inc-bios-short-interest-update.html.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.